MannKind Corporation announced that Chief Executive Officer Michael Castagna will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation coincides with the company's release of fourth quarter and full year 2025 financial results on the same date.
In parallel with the conference participation, MannKind reported the enrollment of its first patient in the INHALE-1ST clinical trial, a pediatric study evaluating the efficacy and safety of Afrezza in young patients with newly-diagnosed Type 1 Diabetes. The trial represents an expansion of the company's clinical development program for its inhalable insulin therapeutic.
The dual announcements reflect MannKind's ongoing efforts to advance its product pipeline while engaging the investment and healthcare communities through major industry conferences. The pediatric study enrollment marks a significant milestone in the company's efforts to explore Afrezza's potential in younger patient populations with Type 1 Diabetes.